Boston Scientific Corporation BSX posted adjusted earnings per share EPS of 31 cents in the third quarter of 2017 up 14 8 from the year ago quarter This figure remained in line with the Zacks Consensus Estimate and fell exactly at the upper end of the company s adjusted EPS guidance range of 29 31 cents Without these adjustments the company reported earnings of 20 cents per share up 17 6 from the year ago period Revenues in the third quarter were up 5 6 year over year on reported basis and up 5 7 on operational basis at constant exchange rate or CER to 2 22 billion The figure topped the company s guidance of 2 18 2 21 billion and also exceeded the Zacks Consensus Estimate of 2 20 billion Organic revenue growth in the third quarter excluding the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings and Symetis SA was 4 3 year over year Geographically in the third quarter the company achieved operational growth of 4 2 in the U S up 2 8 organically up 8 8 in Europe up 5 3 up 7 8 in the Asia Middle East and Africa region same and up 18 3 in the emerging markets up 18 Boston Scientific currently has three global reportable segments Cardiovascular Rhythm Management and MedSurg The company generates maximum revenues from Cardiovascular Sales from its subsegments Interventional Cardiology and Peripheral Interventions were 589 million up 4 2 year over year at CER and 268 million up 5 1 respectively during the third quarter The second largest contributor to Boston Scientific s top line was Rhythm Management which includes Cardiac Rhythm Management CRM and Electrophysiology CRM reflected a 0 9 year over year increase in sales to 463 million at CER in the reported quarter Worldwide sales from pacemakers within CRM declined 4 5 to 149 million while defibrillators were up 0 9 to 314 million Electrophysiology sales went up 17 6 year over year at CER to 71 million Other segments like Endoscopy Urology and Pelvic Health and Neuromodulation under the MedSurg broader group recorded sales of 403 million up 10 at CER 274 million up 10 2 and 154 million up 11 respectively Gross margin contracted 45 basis points bps year over year to 71 3 on 7 2 rise in cost of products sold Adjusted operating margin improved by a marginal 4 bps to 23 2 in the reported quarter During the quarter selling general and administrative expenses went up 3 6 to 800 million while research and development expenses increased 9 5 to 254 million Royalty expenses reduced 20 to 16 million in the quarter Boston Scientific exited the third quarter with cash and cash equivalents of 210 million up from 195 million at the end of the sequential last quarter At the end of the third quarter the company had a total long term debt of 5 68 billion a marginal decline from 5 84 billion at the end of the second quarter Boston Scientific has provided an update to its full year 2017 guidance Banking on a solid third quarter show and a gradually improving foreign exchange scenario the company raised its 2017 revenue guidance to the range of 8 985 9 015 billion annualized growth of 7 8 on reported basis and growth of 7 on operational basis including contribution of approximately 120 bps from EndoChoice and Symetis from the earlier band of 8 89 8 99 billion annualized growth of 6 7 on reported basis and growth of 6 8 on operational basis The current Zacks Consensus Estimate for revenues is 8 95 billion below the guided range Adjusted EPS guidance range for 2017 has been slightly narrowed to 1 24 1 27 from the earlier range of 1 23 1 27 The Zacks Consensus Estimate of 1 25 is within this guided range The company also provided its fourth quarter 2017 financial guidance Adjusted earnings are expected in the band of 32 35 cents per share on revenues of 2 345 2 375 billion The Zacks Consensus Estimate for EPS stands at 34 cents while for revenues it is 2 32 billion Despite back to back natural disasters Boston Scientific managed to register solid third quarter performance with earnings in line with the Zacks Consensus Estimate and revenues ahead of the mark A gradually improving foreign exchange scenario has also started to contribute to the company s overall topline performance The raised guidance is all the more impressive and indicative of this overall bullish trend to continue through the rest of 2017 Boston Scientific is leaving no stone unturned to strengthen its core businesses and invest in new technologies and global markets which accounted for higher sales across all its geographies in the third quarter We are also encouraged with the company gaining a number of approvals for its products both in the domestic and overseas markets Among the recent developments worth mentioning is the company s recent acquisition of Apama Medical the developer of the single shot Apama Radiofrequency RF Balloon Catheter System for the treatment of atrial fibrillation This apart the company received an FDA approval forMRI labeling and announced the U S launch of the Resonate family of implantable cardioverter defibrillator ICD and cardiac resynchronization therapy defibrillator CRT D systems This combines the HeartLogic Heart Failure Diagnostic EnduraLife battery technology and SmartCRT Technology This apart the company received CE Mark for updated Directions for Use for the WATCHMAN LAAC Device in Europe The company s ACURATE neo Transapical Aortic Valve System has also gained CE Mark The company expects to begin a controlled launch throughout Europe during the fourth quarter of 2017 Some other top ranked stocks in the broader medical sector are PetMed Express Inc PETS Abbott ABT and Intuitive Surgical Inc ISRG Notably PetMed sports a Zacks Rank 1 Strong Buy while Abbott and Intuitive Surgical carry a Zacks Rank 2 You can see the complete list of today s Zacks 1 Rank stocks here PetMed reported EPS of 43 cents in second quarter fiscal 2018 up 79 2 from the year ago quarter s 24 cents Also gross margin expanded 548 bps year over year to 35 2 in the reported quarter Abbott reported third quarter 2017 adjusted earnings from continuing operations of 66 cents per share up 11 9 year over year Also third quarter worldwide sales came in at 6 83 billion up 28 8 year over year Intuitive Surgical posted adjusted earnings of 2 77 per share in third quarter 2017 up 34 5 on a year over year basis Also revenues increased 18 year over year to 806 1 million Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation this industry is expected to blast from an already robust 6 7 billion to 20 2 billion in 2021 Early investors stand to make a killing but you have to be ready to act and know just where to look See the pot trades we re targeting Want the latest recommendations from Zacks Investment Research Today you can download 7 Best Stocks for the Next 30 Days Click to get this free report